Last reviewed · How we verify
Febichol (FENIPENTOL)
Febichol (generic name: FENIPENTOL) is a fenipentol drug. It is currently in Phase 2 development.
Febichol is thought to work by interacting with a specific biological target, although this target is currently unknown.
Febichol, also known as FENIPENTOL, is a small molecule drug of the fenipentol class. Its target and exact mechanism of action are unknown. It is not FDA-approved for any indications. The commercial status of Febichol is unclear, and it is not known whether it is patented or available as a generic. Further research is needed to determine its safety and efficacy.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | FENIPENTOL |
|---|---|
| Drug class | fenipentol |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Mechanism of action
Imagine your body's cells are like locks, and Febichol is a key that fits into one of those locks. When it binds to the lock, it can affect how the cell works, but we don't know exactly how it does that yet. This is a simplified way of understanding how Febichol might work, but more research is needed to fully understand its mechanism.
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Febichol CI brief — competitive landscape report
- Febichol updates RSS · CI watch RSS
Frequently asked questions about Febichol
What is Febichol?
How does Febichol work?
What is the generic name of Febichol?
What drug class is Febichol in?
What development phase is Febichol in?
Related
- Drug class: All fenipentol drugs
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing